vs

Side-by-side financial comparison of FRANKLIN FINANCIAL SERVICES CORP (FRAF) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

FRANKLIN FINANCIAL SERVICES CORP is the larger business by last-quarter revenue ($23.3M vs $12.5M, roughly 1.9× Avidity Biosciences, Inc.). FRANKLIN FINANCIAL SERVICES CORP runs the higher net margin — 25.9% vs -1398.3%, a 1424.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 51.5%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 14.6%).

Franklin Financial Services Corp (Pennsylvania) is a U.S. regional bank holding company primarily operating across Pennsylvania. It provides comprehensive retail and commercial banking services, including deposit products, personal and business loans, mortgage financing, and wealth management solutions for individual consumers, small local businesses and regional institutional clients.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FRAF vs RNA — Head-to-Head

Bigger by revenue
FRAF
FRAF
1.9× larger
FRAF
$23.3M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+382.5% gap
RNA
434.0%
51.5%
FRAF
Higher net margin
FRAF
FRAF
1424.3% more per $
FRAF
25.9%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
14.6%
FRAF

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FRAF
FRAF
RNA
RNA
Revenue
$23.3M
$12.5M
Net Profit
$6.0M
$-174.4M
Gross Margin
Operating Margin
32.1%
-1513.5%
Net Margin
25.9%
-1398.3%
Revenue YoY
51.5%
434.0%
Net Profit YoY
1140.7%
-117.0%
EPS (diluted)
$1.35
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FRAF
FRAF
RNA
RNA
Q4 25
$23.3M
Q3 25
$23.0M
$12.5M
Q2 25
$22.3M
$3.8M
Q1 25
$20.2M
$1.6M
Q4 24
$15.4M
$3.0M
Q3 24
$19.5M
$2.3M
Q2 24
$18.6M
$2.0M
Q1 24
$17.7M
$3.5M
Net Profit
FRAF
FRAF
RNA
RNA
Q4 25
$6.0M
Q3 25
$5.4M
$-174.4M
Q2 25
$5.9M
$-157.3M
Q1 25
$3.9M
$-115.8M
Q4 24
$487.0K
$-102.3M
Q3 24
$4.2M
$-80.4M
Q2 24
$3.0M
$-70.8M
Q1 24
$3.4M
$-68.9M
Operating Margin
FRAF
FRAF
RNA
RNA
Q4 25
32.1%
Q3 25
28.9%
-1513.5%
Q2 25
32.8%
-4448.7%
Q1 25
23.9%
-8360.9%
Q4 24
3.4%
-4069.6%
Q3 24
26.2%
-4200.9%
Q2 24
19.8%
-4040.4%
Q1 24
22.6%
-2178.6%
Net Margin
FRAF
FRAF
RNA
RNA
Q4 25
25.9%
Q3 25
23.3%
-1398.3%
Q2 25
26.4%
-4089.3%
Q1 25
19.4%
-7360.0%
Q4 24
3.2%
-3439.5%
Q3 24
21.6%
-3441.7%
Q2 24
16.3%
-3461.8%
Q1 24
18.9%
-1943.4%
EPS (diluted)
FRAF
FRAF
RNA
RNA
Q4 25
$1.35
Q3 25
$1.19
$-1.27
Q2 25
$1.32
$-1.21
Q1 25
$0.88
$-0.90
Q4 24
$0.13
$-0.80
Q3 24
$0.95
$-0.65
Q2 24
$0.66
$-0.65
Q1 24
$0.77
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FRAF
FRAF
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$127.7M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$175.2M
$1.9B
Total Assets
$2.2B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FRAF
FRAF
RNA
RNA
Q4 25
$127.7M
Q3 25
$188.1M
$350.2M
Q2 25
$207.8M
$243.9M
Q1 25
$225.0M
$254.2M
Q4 24
$203.6M
$219.9M
Q3 24
$236.3M
$370.2M
Q2 24
$179.7M
$575.8M
Q1 24
$182.6M
$471.4M
Stockholders' Equity
FRAF
FRAF
RNA
RNA
Q4 25
$175.2M
Q3 25
$166.3M
$1.9B
Q2 25
$157.4M
$1.2B
Q1 25
$151.4M
$1.3B
Q4 24
$144.7M
$1.4B
Q3 24
$149.9M
$1.5B
Q2 24
$136.8M
$1.2B
Q1 24
$134.2M
$830.9M
Total Assets
FRAF
FRAF
RNA
RNA
Q4 25
$2.2B
Q3 25
$2.3B
$2.1B
Q2 25
$2.3B
$1.4B
Q1 25
$2.3B
$1.5B
Q4 24
$2.2B
$1.6B
Q3 24
$2.2B
$1.6B
Q2 24
$2.0B
$1.3B
Q1 24
$2.0B
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FRAF
FRAF
RNA
RNA
Operating Cash FlowLast quarter
$25.4M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
4.21×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FRAF
FRAF
RNA
RNA
Q4 25
$25.4M
Q3 25
$8.3M
$-156.2M
Q2 25
$5.1M
$-199.7M
Q1 25
$8.8M
$-124.8M
Q4 24
$21.8M
$-99.9M
Q3 24
$7.8M
$-65.6M
Q2 24
$2.4M
$-65.0M
Q1 24
$7.3M
$-70.4M
Free Cash Flow
FRAF
FRAF
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
FRAF
FRAF
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
FRAF
FRAF
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
FRAF
FRAF
RNA
RNA
Q4 25
4.21×
Q3 25
1.55×
Q2 25
0.87×
Q1 25
2.25×
Q4 24
44.67×
Q3 24
1.85×
Q2 24
0.80×
Q1 24
2.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons